

May 21, 2021

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Product Registration in Bolivia

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the "Company") have received product registration license for below mentioned one product from the Ministry of Health, Bolivia.

Sr. No.	Name of Product	Therapeutic Category
1	ZOTAMET 850 (Tablet – (Tab – Each Tablet contains Metformin Hydrochloride 850mg)	Antidiabetic

We have received license for the aforementioned product for the validity period of five years; license for the product is also renewable. Company shall start exporting this product in Bolivia soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122